Skip to content

Headache prevalence stayed stable while migraine accounted for much of the disability

This brief uses only the study abstract: global headache prevalence changed little, while disability estimates differed by sex and headache type.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Headache disorders affected a large share of the global population, and prevalence remained broadly stable over the study period. Migraine accounted for much of the estimated disability, with higher headache-related disability rates among females than males. These population estimates describe the scale of the burden, without testing whether any particular treatment prevents disability.

Keep in mind

Estimates depend on modelling and disability weights. The abstract gives too little detail to assess how differences among underlying studies affected uncertainty, and it reports no treatment tests.

THE NUMBERS, WITH CONTEXT

What researchers found

2.9 billion (95% uncertainty interval 2.6–3.1 billion)

People with headache disorders

Global prevalence count in 2023; descriptive population estimate without a treatment comparator.

Lancet Neurol, 2025 · Original source ↓

How burden was estimated

Researchers estimated headache prevalence and time spent with symptoms, then applied disability weights to calculate years lived with disability. This measures population burden rather than counting individuals with diagnosed complications.

How medication overuse was counted

Medication-overuse headache was assigned to the burden of the underlying migraine or tension-type headache. This accounting choice helps interpret the totals; it does not test whether changing medication use reduces an individual's symptoms.

CHECK THE ORIGINAL

The original publication

Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

GBD 2023 Headache Collaborators
Lancet Neurol · 2025

PubMed ID
41240916
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.